In a groundbreaking revelation, scientists have uncovered a vital piece of the puzzle that elucidates the perplexing phenomenon of B cells turning against the body in autoimmune diseases. This discovery not only enhances our understanding of the underlying mechanisms but also opens the door to a potential new treatment approach.
Published in the Journal of Experimental Medicine on September 29, a collaborative research effort led by scientists from Yale University School of Medicine and the Hospital for Special Surgery in New York has revealed that the absence of the TLR9 receptor, present in immune cells called B cells, can trigger these cells to launch attacks on the body’s own tissues. This remarkable finding may hold the key to developing innovative therapies for individuals suffering from conditions such as lupus and scleroderma.
Also Read: BMS Acquires Regional Rights To Zenas’ Obexelimab, A Bifunctional Antibody For Autoimmune Diseases
The researchers emphasized the significance of their findings, stating that, “Our data provide a rationale for the development of novel therapeutic strategies for scleroderma and lupus that will aim at correcting impaired TLR9 function in B cells to restore both central and peripheral B cell tolerance and suppress autoimmune manifestations,”
For years, scientists have recognized that self-reactive B cells contribute to the development of autoimmune diseases. Prior to this study, the prevailing belief was that these rogue cells persisted due to abnormalities in a different receptor known as the B-cell receptor. In normal circumstances, when a developing B cell in the bone marrow binds to a self-antigen found on the body’s cells, other immune cells typically eliminate it through a process called central tolerance. However, certain gene mutations or environmental factors can cause the B-cell receptor to malfunction, allowing it to evade destruction.
This latest research has unveiled a more comprehensive narrative. Building on previous studies that suggested the importance of the TLR9 receptor inside B cells for central tolerance, the scientists investigated the impact of altering this receptor on autoimmune disease development. Initially, they examined the TLR9 responses of B cells from patients with scleroderma and lupus and found that, unlike in healthy cells, the TLR9 receptor did not respond to stimulation, indicating impairment. This link between the receptor and autoimmune disease was subsequently validated in mice, where depleting TLR9 resulted in an increase in self-reactive B cells and antibodies.
The question then arose: What could be causing this dysfunction? Clues emerged from prior research on a signaling protein called CXCL4, which had shown elevated levels in the blood of patients with autoimmune diseases affecting joints, tendons, and bones, such as scleroderma and lupus.
To investigate the interaction between CXCL4 and the TLR9 receptor, the researchers conducted experiments to stimulate the TLR9 receptor in the presence of CXCL4 in both human and mouse B cells. This revealed that signaling molecules crucial for central tolerance were inhibited. Upon closer examination, it became evident that CXCL4 bound to and obstructed the delivery of DNA fragments to TLR9, preventing the upregulation of these molecules and the induction of central tolerance.
Also Read: Hutchmed Sets Sights On Chinese Approval For Autoimmune Disorder Drug Following Phase 3 Triumph
These findings prompted the scientists to explore whether they could replicate these discoveries in animal models. Mice engineered to overexpress CXCL4 exhibited reduced TLR9 activation, an increased presence of self-reactive B cells and antibodies, and diminished B-cell tolerance, as anticipated. This groundbreaking research not only introduces a new dimension to our understanding of autoimmune diseases, revealing a mechanism distinct from B-cell receptor signaling for the removal of self-reactive B cells but also suggests that inhibiting CXCL4 could potentially offer a therapeutic avenue.
Eric Meffre, Ph.D., co-lead of the study (formerly with Yale and now with Stanford), highlighted the implications of these findings, stating, “Correcting defective TLR9 function in B cells from patients with scleroderma and perhaps other autoimmune diseases, potentially by neutralizing CXCL4, may represent a novel therapeutic strategy to restore B cell tolerance.” This revelation brings newfound hope to the quest for effective treatments for autoimmune diseases, offering fresh perspectives and opportunities for patients seeking relief from these debilitating conditions.
